NL-OMON28908
Recruiting
N/A
Phase I trial evaluating combined radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladder.
KI-Av0 sites31 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Bladder carinoma, preservation, radiotherapy, Panitumumab
- Sponsor
- KI-Av
- Enrollment
- 31
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Signed written informed consent;
- •2\. Histologically confirmed bladder carcinoma stage (including previous treatment):
Exclusion Criteria
- •1\. Evidence of M\+ (all patients will undergo a pelvic lymphadenectomy prior to chemoradiation);
- •2\. Prior chemotherapy or radiotherapy to the pelvis;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Phase I trial evaluating combined radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladderbladder cancerBladder carcinoma10004994NL-OMON34833Antoni van Leeuwenhoek Ziekenhuis31
Completed
Phase 1
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckNCT03635164University of Colorado, Denver21
Recruiting
Phase 1
Phase I study for simultaneous radiochemotherapy of relapsed ovarian cancerC51-C58Malignant neoplasms of female genital organsDRKS00008552niversitätsklinikum für Strahlentherapie6
Recruiting
Phase 1
Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCCLocally Advanced Skin Squamous Cell CarcinomaResectable Skin Squamous Cell CarcinomaUnresectable Skin Squamous Cell CarcinomaNCT05085496City of Hope Medical Center12
Unknown
Phase 1
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal CancerRectal CancerNCT01716949University of Erlangen-Nürnberg Medical School59